- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.07. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.07.2025 | 1.040 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 14.07.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.07.2025ISIN NameDK0061031895 SCANDION... ► Artikel lesen | |
| SCANDION ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 14.07. | XFRA 8VY: AUSSETZUNG/SUSPENSION | 201 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSCANDION ONC. DK-... ► Artikel lesen | |
| 25.06. | Scandion Oncology A/S: Delisting of the shares of Scandion Oncology - last day of trading July 11, 2025 | 234 | GlobeNewswire (Europe) | In accordance with Nasdaq Stockholm AB's decision, following application from the liquidator of Scandion Oncology, the shares of Scandion Oncology will be delisted from Nasdaq First North Growth Market.... ► Artikel lesen | |
| 25.06. | The observation status for Scandion Oncology A/S is updated | 186 | GlobeNewswire | On February 27, 2025, the shares in Scandion Oncology A/S (the "Company") were given observation status with reference to information that the Company's board of directors would, if a partnership... ► Artikel lesen | |
| 25.06. | Scandion Oncology A/S: Scandion Oncology has applied for delisting of the company's shares from Nasdaq First North Growth Market | 195 | GlobeNewswire (Europe) | The liquidator of Scandion Oncology (the "Company") has today submitted an application for delisting of the Company's shares from Nasdaq First North Growth Market. The last day of trading in the Company's... ► Artikel lesen | |
| 27.03. | Scandion Oncology A/S: Scandion Oncology Announces Results of Annual General Meeting | 205 | GlobeNewswire (Europe) | The Annual General Meeting 2025 of Scandion Oncology A/S in liquidation (the "Company") was held on 27 March 2025 at 2:00 p.m.
All proposals were adopted in accordance with the notice.As such, the Company... ► Artikel lesen | |
| 13.03. | The observation status for Scandion Oncology A/S is updated | 272 | GlobeNewswire | On February 27, 2025, the shares and equity rights in Scandion Oncology A/S (the "Company") were given observation status with reference to information that the Company's board of directors would... ► Artikel lesen | |
| 13.01. | Scandion Oncology A/S: Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer | 227 | GlobeNewswire (Europe) | Scandion Oncology, an innovative drug efflux pump inhibition company using biomodulation capability to revert drug resistance, announces final data from CORIST trial part 1, 2 and 3. In this phase I/II... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 71,54 | +0,27 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| POLYRIZON | 7,330 | 0,00 % | Polyrizon Ltd.: Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform | Ra'anana, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,250 | +12,67 % | Why Vera Therapeutics Stock Rocked the Market on Tuesday | ||
| COGENT BIOSCIENCES | 38,980 | 0,00 % | Aktien New York: Gewinne dank Signalen für Shutdown-Ende | NEW YORK (dpa-AFX) - An den US-Börsen knüpfen die Kurse am Montag mit einer Erholung an die späte Kursstabilisierung vom Freitag an. Wie schon zuvor in Asien und Europa hellten Anzeichen für eine mögliche... ► Artikel lesen | |
| JANUX THERAPEUTICS | 15,820 | 0,00 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| IMMUNOVANT | 22,020 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,150 | -3,90 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 40,405 | -1,42 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| NUVALENT | 104,96 | -1,37 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,430 | -3,10 % | Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales | ||
| KYMERA THERAPEUTICS | 64,27 | -3,87 % | Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? | ||
| APOGEE THERAPEUTICS | 69,13 | +0,41 % | Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results | Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,010 | +1,44 % | Harmony Biosciences to present Dravet syndrome trial data at AES meeting | ||
| DISC MEDICINE | 89,72 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 178,96 | -3,03 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen |
SCANDION ONCOLOGY A/S gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,001 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCANDION ONCOLOGY A/S finden Sie auf Wallstreet Online.